Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glycogen Storage Disease Type II: full-pipeline trial registry
1 of 4 indexed Glycogen Storage Disease Type II trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Glycogen Storage Disease Type II: 4 US clinical trials tracked, 1 recruiting.
Glycogen Storage Disease Type II is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 2 of these trials.
Enrollment posture brief
Registry condition glycogen-storage-disease-type-ii
OPEN 1 | RECR 25% | LATE 1 | EARLY 1 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Glycogen Storage Disease Type II lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glycogen Storage Disease Type II on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glycogen Storage Disease Type II is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Pompe Disease Registry Protocol
Genzyme, a Sanofi Company
NCT00231400
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
Sanofi
NCT04910776
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
Sanofi
NCT04848779
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
Spark Therapeutics
NCT04093349
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glycogen Storage Disease Type II records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glycogen Storage Disease Type II trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glycogen Storage Disease Type II page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Glycogen Storage Disease Type II trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sanofi sponsors the most Glycogen Storage Disease Type II trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glycogen Storage Disease Type II condition card totals 4 registered trials; most-linked intervention Alglucosidase alfa GZ419829; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.